摘要
目的研究恩替卡韦联合乳果糖治疗乙型肝炎(乙肝)后肝硬化的临床疗效。方法选取2017年1月至2019年12月本院收治的108例乙肝后肝硬化患者作为研究对象,按照随机数字表法分为两组,每组54例。对照组采用恩替卡韦治疗,观察组在对照组基础上联合乳果糖治疗,比较两组炎症因子水平、肝功能和肝纤维化指标。结果治疗6个月后,观察组IL-6、IL-8、TNF-α水平均低于对照组(P<0.05);治疗6个月后,观察组AST、ALT、TBIL水平均低于对照组(P<0.05);治疗6个月后,观察组LN、HA、PCⅢ、ⅣC水平均低于对照组(P<0.05)。结论恩替卡韦联合乳果糖治疗乙肝后肝硬化能显著控制炎症因子水平,改善肝功能,减轻肝纤维化,值得临床推广应用。
Objective To study the clinical efficacy of entecavir combined with lactulose in the treatment of liver cirrhosis after hepatitis B.Methods 108 patients with liver cirrhosis after hepatitis B from January 2017 to December 2019 in our hospital were selected as the research subjects,and they were divided into two groups according to random number table method,with 54 cases in each group.The control group were treated with entecavir,the observation group were treated with lactulose on the basis of control group.The levels of inflammatory factors,liver function and liver fibrosis indexes between the two groups was compared.Results After 6 months of treatment,the levels of IL-6,IL-8 and TNF-αin the observation group were lower than those in the control group(P<0.05);after 6 months of treatment,the levels of AST,ALT and TBIL in the observation group were lower than those in the control group(P<0.05);after 6 months of treatment,the levels of LN,HA,PCⅢandⅣC in the observation group were lower than those in the control group(P<0.05).Conclusion Entecavir combined with lactulose in the treatment of posthepatitic cirrhosis can control the inflammatory level,i mprove liver function and reduce liver fibrosis,and it is worth popularizing.
作者
陈尚军
张继
谢虎生
CHEN Shangjun;ZHANG Ji;XIE Husheng(Department of Infectious Disease,Naval Hospital of Eastern Theater of PLA,Zhoushan,Zhejiang,316000,China)
出处
《当代医学》
2022年第9期40-42,共3页
Contemporary Medicine
关键词
乙型肝炎
肝硬化
恩替卡韦
乳果糖
治疗
疗效
Hepatitis B
Cirrhosis
Entecavir
Lactulose
Treatment
Curative effect
